Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer

NCT03668431 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03668431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03668431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 15, 2018
Completion date
December 1, 2022
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer